Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12350625 | 1.00 | TRPV1 (0.42) | TRPV1HCRTR1HCRTR2TRPA1PDE10A | |
| SCHEMBL12350627 | 1.00 | TRPV1 (0.42) | TRPV1HCRTR1HCRTR2TRPA1PDE10A | |
| SCHEMBL12350621 | 1.00 | TRPV1 (0.42) | TRPV1HCRTR1HCRTR2TRPA1PDE10A | |
| SCHEMBL12350594 | 1.00 | TRPV1 (0.42) | TRPV1HCRTR1HCRTR2TRPA1PDE10A | |
| SCHEMBL1797611 | 0.91 | TRPV1 (0.50) | TRPV1HCRTR1HCRTR2TRPA1PDE10A | |
| SCHEMBL1796567 | 0.89 | TRPV1 (0.52) | TRPV1TRPA1ROCK2 | |
| SCHEMBL1802866 | 0.89 | TRPV1 (0.52) | TRPV1TRPA1ROCK2 | |
| SCHEMBL1796813 | 0.89 | TRPV1 (0.52) | TRPV1TRPA1ROCK2 | |
| SCHEMBL1800653 | 0.89 | TRPV1 (0.52) | TRPV1TRPA1ROCK2 | |
| SCHEMBL1801566 | 0.89 | TRPV1 (0.41) | TRPV1HCRTR1HCRTR2TRPA1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885HCRTR1 3055/4885HCRTR2 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.